Shares of Ionis Pharmaceuticals Inc (NASDAQ:IONS) have been assigned a consensus rating of “Hold” from the eleven research firms that are presently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and two have given a buy rating to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $62.63.
A number of equities analysts have issued reports on IONS shares. Zacks Investment Research upgraded Ionis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $58.00 target price on the stock in a report on Wednesday, January 2nd. ValuEngine upgraded Ionis Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Thursday, February 28th. BMO Capital Markets raised their target price on Ionis Pharmaceuticals from $70.00 to $82.00 and gave the stock an “outperform” rating in a report on Thursday, February 28th. Piper Jaffray Companies raised their target price on Ionis Pharmaceuticals to $60.00 and gave the stock a “neutral” rating in a report on Thursday, February 28th. Finally, Morgan Stanley set a $71.00 target price on Ionis Pharmaceuticals and gave the stock a “hold” rating in a report on Friday, March 1st.
Ionis Pharmaceuticals stock traded down $0.81 during mid-day trading on Wednesday, hitting $83.80. The stock had a trading volume of 26,001 shares, compared to its average volume of 1,141,285. The stock has a market cap of $11.70 billion, a price-to-earnings ratio of 28.30, a P/E/G ratio of 256.41 and a beta of 2.42. Ionis Pharmaceuticals has a 12 month low of $39.07 and a 12 month high of $86.58. The company has a quick ratio of 7.85, a current ratio of 7.88 and a debt-to-equity ratio of 0.53.
Ionis Pharmaceuticals (NASDAQ:IONS) last posted its quarterly earnings results on Wednesday, February 27th. The company reported $2.42 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.04) by $2.46. The business had revenue of $192.00 million for the quarter, compared to analysts’ expectations of $159.59 million. Ionis Pharmaceuticals had a return on equity of 41.89% and a net margin of 45.64%. During the same quarter last year, the business earned ($0.03) earnings per share. The firm’s quarterly revenue was up 14.3% compared to the same quarter last year. As a group, sell-side analysts expect that Ionis Pharmaceuticals will post 0.02 EPS for the current year.
In other news, SVP Richard S. Geary sold 999 shares of Ionis Pharmaceuticals stock in a transaction dated Wednesday, February 13th. The stock was sold at an average price of $60.00, for a total transaction of $59,940.00. Following the transaction, the senior vice president now owns 21,442 shares in the company, valued at approximately $1,286,520. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP C Frank Bennett sold 9,013 shares of Ionis Pharmaceuticals stock in a transaction that occurred on Friday, February 1st. The shares were sold at an average price of $58.29, for a total value of $525,367.77. Following the completion of the sale, the senior vice president now directly owns 33,541 shares in the company, valued at approximately $1,955,104.89. The disclosure for this sale can be found here. Insiders have sold a total of 339,205 shares of company stock worth $24,034,607 in the last quarter. 2.44% of the stock is currently owned by company insiders.
Institutional investors have recently made changes to their positions in the stock. Huntington National Bank raised its position in Ionis Pharmaceuticals by 159.3% in the 4th quarter. Huntington National Bank now owns 638 shares of the company’s stock valued at $34,000 after buying an additional 392 shares during the last quarter. Essex Savings Bank acquired a new position in shares of Ionis Pharmaceuticals during the 4th quarter worth approximately $39,000. Laurel Wealth Advisors LLC acquired a new position in shares of Ionis Pharmaceuticals during the 4th quarter worth approximately $43,000. Daiwa Securities Group Inc. increased its position in shares of Ionis Pharmaceuticals by 29.0% during the 4th quarter. Daiwa Securities Group Inc. now owns 890 shares of the company’s stock worth $48,000 after purchasing an additional 200 shares during the last quarter. Finally, Portfolio Solutions LLC acquired a new position in shares of Ionis Pharmaceuticals during the 4th quarter worth approximately $54,000. 85.05% of the stock is currently owned by institutional investors and hedge funds.
Ionis Pharmaceuticals Company Profile
Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.
Featured Story: Cost of Debt
Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.